HROW Harrow Health Inc.

Harrow to Present at Two Investor Conferences in December

Harrow to Present at Two Investor Conferences in December

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December:

BTIG 5th Annual Ophthalmology Day (Virtual)

Format: Fireside chat

Date/Time: Monday, December 1, 2025, at 8:30 AM EST

Piper Sandler 37th Annual Healthcare Conference (New York, NY)

Format: Fireside chat

Date/Time: Tuesday, December 2, 2025, at 3:00 PM EST

The fireside chat at Piper Sandler will be webcast live and can be found on the Event’s page on the . A replay will be available for approximately 90 days following the event.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit

Contacts:

Mike Biega

Vice President of Investor Relations and Communications        

        

617-913-8890



EN
24/11/2025

Underlying

HROWHarrow Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million,...

Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow’s Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow’s ImprimisRx Settles Pending Regulatory Matters with...

February 2, 2026 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow to Present at Two Investor Conferences in December

Harrow to Present at Two Investor Conferences in December NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Pi...

November 24, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals

Harrow Announces Closing of Acquisition of Melt Pharmaceuticals NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolvi...

November 18, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Third Quarter 2025 Financial Results

Harrow Announces Third Quarter 2025 Financial Results Third-Quarter 2025 and Recent Selected Highlights:  Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its thi...

November 10, 2025 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow To Report Third Quarter 2025 Financial Results After Market Clo...

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors”...

October 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch